Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. GS
4. BAC
5. DRS
6. AVAV
7. ACI
8. UNH
9. ORCL
10. JPM

Go back to Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

October 1, 2018 6:45 AM EDT

-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy-

-Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall Survival-

-First Randomized Phase 3 Trial to Show Improvement in Overall Survival in Frontline Peripheral T-Cell Lymphoma-

-Data to be Presented at the 2018 ASH Annual Meeting; Global Regulatory Submissions Planned-

BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--... More